35 results about "Sugar binding" patented technology

Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

A method for enhancing a binding activity of an antibody composition to Fcγ receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcγ receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.

Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Belonging to the technical field of refractory material preparation, the invention relates to a preparation method of a glucose combined magnesia carbon brick. The method adopts magnesite (fused magnesite or sintered magnesite) and a carbon raw material (flake graphite, carbon black or electrode chip) as the main raw materials, glucose is added as a binding agent and other additives are added, and by means of compounding, mixing, aging, molding, drying and other technological processes are carried out to obtain a non-fired magnesia carbon brick. The refractory material provides low temperature strength through the glucose binding agent, and the glucose binding agent undergoes thermal decomposition and carbonization to form a carbon structure so as to provide medium and high temperature strength. Compared with the traditional phenolic resin combined magnesia carbon brick, the glucose combined magnesia carbon brick has the advantages of environmental friendliness and low cost. The preparation method also provides the technical and theoretical basis for application of glucose binding agent to other high-temperature resistant materials.

The present invention discloses a processing method of sausages. By adding L-arginine, L-lysine, L-cysteine, sodium nitrite and L-ascorbic acid into meat paste according to a certain ratio, the sausages are prepared by pickling, filling and boiling, so that a red value is increased by 10%-17%, a brightness value is increased by 6%-12%. The method plays a role in improving and stabilizing color and luster. A water boiling at 75-80 DEG C prevents myoglobin oxidation and poor color and luster production caused by excessive high temperatures. The method keeps the original tissue structures and nutrients of the meat products, and is line with the development trends of the meat products. Amino acids are combined with sugars to produce flavor substances and improve product flavor. The residual amount of the sodium nitrite is 4.5-10 mg / kg, which is far below the national standard and accepted by the vast number of consumers.

This invention provides a donor bead for use in an assay, wherein the bead (a) is coated with a layer of hydrogel having directly or indirectly bound thereto a polyacrylamide-supported sugar or a polyacrylamide-supported glycan, and (b) comprises a photosensitizer which, upon excitation by laser light of a suitable wavelength, converts ambient oxygen to singlet state oxygen. This invention also provides an acceptor bead for use in an assay, wherein the bead (a) is coated with a layer of hydrogel having directly or indirectly bound thereto a polyacrylamide-supported sugar or a polyacrylamide-supported glycan, and (b) comprises a chemiluminescer and a fluorophore, whereby when the bead is contacted with singlet state oxygen, the singlet state oxygen reacts with the chemiluminescer which in turn activates the fluorophore so as to cause the emission of light of a predetermined wavelength. This invention further provides related kits, detection methods and characterization methods.

The invention belongs to the field of special ceramic material preparation processes and relates to an improved ceramic grouting and molding method. The method comprises the steps of proportioning; mixing and carrying out ball milling; removing air bubbles; pouring; settling slurry; discharging superfluous slurry; demolding and drying; and sintering. According to the method, a proper amount of organic sugar water solution is added in the slurry preparation process, organic sugar plays a role as a binding agent beneficial to improvement of strength of a blank obtained after slurry is settled, and the blank does not easily deform and crack in the drying and sintering processes, so that a non-deformable and defect-free ceramic part can be obtained. Only a small quantity of dispersing agent and sugar binding agent are added in the slurry preparation process, so that the content of organic matters in slurry is greatly reduced as comparison with the content of organic matters in slurry obtained by using the traditional grouting method; and due to the reduction of the organic matters, holes generated by discharging the organic matters in the sintering process of the ceramic part can be reduced, the ceramic density can be increased, and furthermore the strength of the ceramic can be improved.

The invention provides a wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticle preparation and a preparation method thereof, relating to the technical field of medicines. In the invention, an ion cross-linking method is used for preparing salmeterol xinafoate chitosan nanoparticles; and by utilizing the characteristic that the alveolar epithelium has specific sugar receptor N-acetyl glucosamine, wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticles are prepared, so that the specific sugar receptor N-acetyl glucosamine of the alveolar epithelium can be combined through the wheat germ agglutinin to enable the salmeterol xinafoate chitosan nanoparticles to have the targeting property of guiding the alveolar membrane. In-vitro sugar-binding test results show that the wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticles have the advantage of guiding the alveolar membrane, thus the administration dosage can be lowered, and the toxic side effect can be reduced; and by the slow release of the medicament, the effective concentration maintaining time of the medicament in the lung is long, thereby enhancing the treatment effect. The preparation provided by the invention can be used for preparing medicaments for treating asthma, chronic bronchitis or chronic obstructive pulmonary disease.

An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Provides a new method of enhancing autoimmunity by administering a specific active ingredient that does not lose its sugar binding property due to heating, shows good selectivity for recognizing sugar chains, and activates cellular immunity Autoimmune enhancing activity such as ability. The active ingredient is obtained by the following method: in the extract liquid extracted from Gracilaria red algae with saline solution, by adding ammonium sulfate so that the final concentration reaches 20-40% saturation concentration to carry out the first stage of salting out, Remove the precipitated impurities, and then further add ammonium sulfate to make the final concentration reach 60-80% saturation concentration to carry out the second stage of salting out, recover the crude active fraction in the form of precipitation, and obtain liquid crude Active fraction; if necessary, remove impurity proteins by heat treatment at 100°C for 1 to 10 minutes, then separate fractions with a molecular weight of 100,000 or more by gel filtration chromatography, and further separate the components by chromatography, collect and display The active ingredient is obtained by activating the fraction of cellular immunity.

The invention discloses a preparation method of soft sweets with functions of protecting liver and dispelling effects of alcohol. The preparation method comprises the following steps: S1, compounding and dissolving raw materials and auxiliary materials; S2, boiling sugar; S3, blending, S4, filtering, S5, forming; S6, transferring the shaped crude soft sweets into a twisting machine and a shearing machine to obtain soft sweet particles, and then discharging the soft sweet particles and placing the soft sweet particles into a bearing device; and S7, dehumidifying and drying. According to the preparation method, a sweetening agent and a gel are taken as main components, moisture and nutrient substances are locked through processes of vacuum boiling of a gum sugar solution, addition of a nutrition enhancer, taste adjustment and the like, the gum sugar solution is filled into a collagen casing to combine the nutrient components, the moisture and the soft sweets, and then the processes of twisting, shearing, drying and the like are conducted to prepare the soft sweets, and the soft sweets have certain elasticity and chewiness; and according to the traditional Chinese medicine food source theory, radix puerariae, hovenia dulcis thunb, sea-buckthorn, emblic leafflower fruit, fingered citron and fermented turmeric are used as main anti-alcohol components.

Disclosed herein are staphylococcal and enterococcal glycoconjugate vaccines for the prevention or treatment of bacterial infections in immunocompromised individuals. The vaccine consists of an immunizing vector and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically pathogenic bacterial strain. The vaccine can be used for active protection of immunocompromised individuals in settings where there is an immediate risk of bacterial infection, such as during intubation or surgery.

[Problem] To provide a method that increases the detection level of a reaction product generated through a reaction between a glycoprotein and a carbohydrate-binding compound in order to detect the glycoprotein with high precision.[Solution] A method for detecting a glycoprotein according to the present invention comprising the steps of: subjecting a sample containing the glycoprotein to a protease treatment; allowing the protease-treated glycoprotein to react with a sugar-binding compound having affinity with a glycan contained in the glycoprotein in order to obtain a reaction product between the glycoprotein and the sugar-binding compound; and detecting the reaction product. The sugar-binding compound is preferably a sugar-binding protein.

A protein and sugar combined protein with anti-HIV activity is from Serpulalacrymans, Serpulavermicularis or Serpula rhizomorphs. It has anti-virus of human acquired immune system syndrome activity and amino acid sequence of SEQ ID No.1. It has no-toxic for human T lymphocytes system C8166 cell. It can express the sugar protein in yeast by 15 amino acid sequences at N end. Its structural analog is an anti-AIDS medicinal guiding compound.

A method of removing serum albumin from blood serum or plasma includes contacting the blood serum or plasma with a sugar-binding protein such as a lectin (e.g., Concanavalin A or wheat germ agglutinin) immobilized on an insoluble support such as a porous bead (e.g., agarose). The method may be practiced by immobilizing a sugar-binding protein on an insoluble support, preparing blood serum or plasma for contacting with the insoluble support having the sugar-binding protein immobilized thereon, contacting the prepared blood serum or plasma with the insoluble support having the sugar-binding protein immobilized thereon to absorb glycosylated proteins from the blood serum or plasma leaving an unbound fraction containing serum albumin, and differentially eluting glycosylated proteins with different sugars from the insoluble support contacted with the blood serum or plasma.

A two-chain insulin analogue contains an A chain modified by (i) a monomeric glucose-binding element at or near its N terminus and (ii) a B chain modified by at or near its C terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated). The B chain may be modified by a diol-containing element derived from a monosaccharide, disaccharide or oligosaccharide, a non-saccharide diol-containing moiety or a [Alpha]-hydroxycarboxylate-containing moiety. The analogue can be manufactured by trypsin-mediated semi-synthesis. Formulations can be at strengths U-10 to U-1000 in soluble solutions at pH 7.0-8.0 with or without zinc ions at a molar ratio of 0.0-3.0 ions per insulin analogue monomer. A patient with diabetes mellitus may be treated with subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the insulin analogue.

The present application belongs to the field of biology, and provides amphioxus C-type lectin BjCTL4 gene and application thereof. The protein encoded by the C-type lectin BjCTL4 gene discovered for the first time in this application, its CTL-like domain has the basic features of traditional CTL, including two or three pairs of conserved disulfide bonds, a motif similar to the characteristic motif WIGL, and with Ca 2+ Similar motifs of related sugar-binding motifs QPD / EPN and WND have been preliminarily verified to be able to extensively bind polysaccharides on the surface of bacteria, and have obvious bacterial binding and bacterial agglutination, which can be developed into natural antibacterial active substances and preparations. Medicines to treat infectious diseases.

The invention relates to a carbohydrate chip method for screening a carbohydrate binding protein competitive inhibitor. On the basis that a carbohydrate chip technology is used for screening protein receptors, the inhibitor is added to cause the change of the fluorescence intensity of the known binding protein, so that the screening of the inhibitor of the known protein and the comparison of the competitiveness of the inhibitor are realized. According to the invention, the original screening function of the sugar chip technology is broken through, and the application of the sugar chip technology is expanded. The method can be used for carrying out primary affinity comparison on different sugar binding proteins and screening inhibitors with relatively strong competitiveness, and is simple, convenient and rapid to operate, small in protein dosage and high in feasibility. In addition, the method can also be applied to other biological chips, such as protein chips and gene chips.

The invention provides a wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticle preparation and a preparation method thereof, relating to the technical field of medicines. In the invention, an ion cross-linking method is used for preparing salmeterol xinafoate chitosan nanoparticles; and by utilizing the characteristic that the alveolar epithelium has specific sugar receptor N-acetyl glucosamine, wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticles are prepared, so that the specific sugar receptor N-acetyl glucosamine of the alveolar epithelium can be combined through the wheat germ agglutinin to enable the salmeterol xinafoate chitosan nanoparticles to have the targeting property of guiding the alveolar membrane. In-vitro sugar-binding test results show that the wheat germ agglutinin modified salmeterol xinafoate chitosan nanoparticles have the advantage of guiding the alveolar membrane, thus the administration dosage can be lowered, and the toxic side effect can be reduced; and by the slow release of the medicament, the effective concentration maintaining time of the medicament in the lung is long, thereby enhancing the treatment effect. The preparation provided by the invention can be used for preparing medicaments for treating asthma, chronic bronchitis or chronic obstructive pulmonary disease.

Provided is a glycosaminoglycan-producing promoter containing, as an active ingredient, an inositol derivative in which sugar binds to inositol. Also provided is a composition for promoting glycosaminoglycan production, the composition containing: said glycosaminoglycan-producing promoter; and a pharmaceutically acceptable carrier.

The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and / or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and / or DOPA decarboxylse inhibitor / s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.

Sodium cyanoborohydride (NaCNBH 3 ) can reduce the aldehyde group formed by the oxidation of polysaccharide by sodium periodate and the amino group of the protein to form a C=N double bond, which promotes the combination of sugar and protein, thereby being used in the preparation process of polysaccharide-conjugated vaccine; the invention provides a polysaccharide residual NaCNBH in conjugate vaccine 3 Ion Chromatography-Pulsed Amperometric Detection Method, comprising the steps of: using NaCNBH 3 Prepare the reference solution from the standard product; centrifuge the sample to be tested with an ultrafiltration centrifuge tube, collect the filtrate and filter it with a 0.45 μm membrane as the test solution; the test solution and the reference solution NaCNBH 3 Load the sample on the ion chromatographic column respectively, elute after loading the sample, and record the chromatogram; according to the reference substance solution NaCNBH 3 Concentration and its chromatographic peak area, need testing solution NaCNBH 3 Chromatographic peak area, using external standard method to calculate NaCNBH in the sample 3 concentration. The method of the present invention is simple, easy to operate, and high in accuracy, and can accurately and quickly realize the residual NaCNBH in the polysaccharide-conjugated vaccine 3 effective monitoring.

Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.

Sodium cyanoborohydride (NaCNBH3) can reduce aldehyde groups formed by oxidizing polysaccharide through sodium periodate and amino groups of protein to form C = N double bonds, combination of sugar and protein is promoted, and therefore the sodium cyanoborohydride (NaCNBH3) is used in the preparation process of the polysaccharide conjugate vaccine. The invention provides an ion chromatography-pulse ampere detection method for residual NaCNBH3 in a polysaccharide conjugate vaccine. The method comprises the following steps: preparing a reference substance solution by using a NaCNBH3 standard substance; centrifuging the sample to be detected by using an ultrafiltration centrifuge tube, collecting filtrate, and filtering the filtrate by using a 0.45 mu m membrane to obtain a test solution; respectively loading the test solution and the reference solution NaCNBH3 to an ion chromatographic column, eluting after loading, and recording chromatograms; and calculating the concentration of NaCNBH3 in the test sample by adopting an external standard method according to the concentration of NaCNBH3 in the reference substance solution, the chromatographic peak area of NaCNBH3 in the test samplesolution and the chromatographic peak area of NaCNBH3 in the test sample solution. The method disclosed by the invention is simple, convenient to operate, high in accuracy and capable of accurately and quickly realizing effective monitoring of residual NaCNBH3 in the polysaccharide conjugate vaccine.

An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

The invention belongs to the field of biology, and provides a Branchiostoma belcheri C-type lectin BjCTL4 gene and application thereof. A protein coded by the C-type lectin BjCTL4 gene is found for the first time, a CTL-like structural domain of the protein has basic characteristics of traditional CTL, the protein comprises two or three pairs of conservative disulfide bonds, similar motifs of a characteristic motif WIGL and similar motifs of Ca < 2 + >-related sugar binding motifs QPD / EPN and WND, and the protein can be widely combined with polysaccharides on the surfaces of bacteria through preliminary verification, has obvious bacterial binding and bacterial agglutination effects, and can be developed into a natural antibacterial active substance and used for preparing medicines for treating infectious diseases.